Alnylam Pharmaceuticals admitted defeat, for now, in a lawsuit in Delaware federal court that accused Moderna's blockbuster ...
The FDA in 2022 approved Amvuttra to treat adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis, a rare debilitating disease that damages nerves, and analysts have predicted ...
Scholar Rock yesterday reported that its experimental treatment for spinal muscular atrophy succeeded in a Phase 3 trial, ...
With the business potentially at an important milestone, we thought we'd take a closer look at Alnylam Pharmaceuticals, ...
Newly launched Judo Bio aims to develop ligand-siRNA conjugates through its Selectively Targeting RNA Into KidnEy (STRIKE) ...
A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...
Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined.
City Therapeutics, based in Cambridge, is developing new medicines that use RNA interference, or RNAi, to silence genes and ...
The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.
Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...
Zacks.com on MSN22h
RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy TagUltragenyx announces that the FDA grants Breakthrough Therapy designation to its investigational osteogenesis imperfecta ...
The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback